BETTER THERAPEUTICS INC (BTTX) Stock Price & Overview

NASDAQ:BTTX • US08773T1043

Current stock price

0.0446 USD
+0.01 (+27.43%)
At close:
0.036 USD
-0.01 (-19.28%)
After Hours:

The current stock price of BTTX is 0.0446 USD. Today BTTX is up by 27.43%. In the past month the price decreased by -78.14%. In the past year, price decreased by -95.79%.

BTTX Key Statistics

52-Week Range0.0308 - 1.61
Current BTTX stock price positioned within its 52-week range.
1-Month Range0.0308 - 0.24
Current BTTX stock price positioned within its 1-month range.
Market Cap
2.224M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-1.15
Dividend Yield
N/A

BTTX Stock Performance

Today
+27.43%
1 Week
-79.26%
1 Month
-78.14%
3 Months
-82.23%
Longer-term
6 Months -91.09%
1 Year -95.79%
2 Years -97.75%
3 Years N/A
5 Years N/A
10 Years N/A

BTTX Stock Chart

BETTER THERAPEUTICS INC / BTTX Daily stock chart

BTTX Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to BTTX. When comparing the yearly performance of all stocks, BTTX is a bad performer in the overall market: 99.79% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

BTTX Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to BTTX. Both the profitability and financial health of BTTX have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

BTTX Earnings

Next Earnings DateMar 27, 2024
Last Earnings DateNov 9, 2023
PeriodQ3 / 2023
EPS Reported-$0.15
Revenue Reported
EPS Surprise 24.59%
Revenue Surprise %

BTTX Forecast & Estimates

8 analysts have analysed BTTX and the average price target is 5.36 USD. This implies a price increase of 11906.73% is expected in the next year compared to the current price of 0.0446.

For the next year, analysts expect an EPS growth of 50.82% and a revenue growth -100% for BTTX


Analysts
Analysts82.5
Price Target5.36 (11917.94%)
EPS Next Y50.82%
Revenue Next Year-100%

BTTX Groups

Sector & Classification

Index Membership

BTTX Financial Highlights

Over the last trailing twelve months BTTX reported a non-GAAP Earnings per Share(EPS) of -1.15. The EPS increased by 43.07% compared to the year before.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)-31.58M
Industry RankSector Rank
PM (TTM) N/A
ROA -294.55%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%68.75%
Sales Q2Q%N/A
EPS 1Y (TTM)43.07%
Revenue 1Y (TTM)N/A

BTTX Ownership

Ownership
Inst Owners0.01%
Shares49.86M
Float23.27M
Ins Owners17.48%
Short Float %0%
Short Ratio0

About BTTX

Company Profile

BTTX logo image Better Therapeutics, Inc. operates as a digital therapeutics company, which engages in developing a novel form of cognitive behavioral therapy to address the root causes of cardio metabolic diseases. The company is headquartered in San Francisco, California and currently employs 54 full-time employees. The company went IPO on 2021-01-08. The firm is engaged in developing a novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases. Its lead PDT product candidate, BT-001, is an investigational prescription digital therapy for the treatment of T2D. The investigational therapy is delivered via software that provides a tailored experience to patients designed to help them address the underlying causes of T2D by making meaningful, sustainable behavioral changes. The BT-001 investigational therapy is rooted in the well-studied, gold standard of behavioral modification therapies, cognitive behavioral therapy (CBT). The firm's platform consists of three behavioral therapy, treatment plans and personalization. Its behavioral therapy consists of lessons, skill- building modules, and a mechanism for goal setting. Its treatment plan is the primary engagement interface for patients.

Company Info

IPO: 2021-01-08

BETTER THERAPEUTICS INC

548 Market St. #49404

San Francisco CALIFORNIA US

CEO: Suying Liu

Employees: 54

BTTX Company Website

Phone: 14158872311

BETTER THERAPEUTICS INC / BTTX FAQ

What does BTTX do?

Better Therapeutics, Inc. operates as a digital therapeutics company, which engages in developing a novel form of cognitive behavioral therapy to address the root causes of cardio metabolic diseases. The company is headquartered in San Francisco, California and currently employs 54 full-time employees. The company went IPO on 2021-01-08. The firm is engaged in developing a novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases. Its lead PDT product candidate, BT-001, is an investigational prescription digital therapy for the treatment of T2D. The investigational therapy is delivered via software that provides a tailored experience to patients designed to help them address the underlying causes of T2D by making meaningful, sustainable behavioral changes. The BT-001 investigational therapy is rooted in the well-studied, gold standard of behavioral modification therapies, cognitive behavioral therapy (CBT). The firm's platform consists of three behavioral therapy, treatment plans and personalization. Its behavioral therapy consists of lessons, skill- building modules, and a mechanism for goal setting. Its treatment plan is the primary engagement interface for patients.


What is the stock price of BETTER THERAPEUTICS INC today?

The current stock price of BTTX is 0.0446 USD. The price increased by 27.43% in the last trading session.


Does BTTX stock pay dividends?

BTTX does not pay a dividend.


What is the ChartMill technical and fundamental rating of BTTX stock?

BTTX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.


Where is BETTER THERAPEUTICS INC (BTTX) stock traded?

BTTX stock is listed on the Nasdaq exchange.


Can you provide the sector and industry classification for BETTER THERAPEUTICS INC?

BETTER THERAPEUTICS INC (BTTX) operates in the Health Care sector and the Health Care Technology industry.


What is the Price/Earnings (PE) ratio of BETTER THERAPEUTICS INC (BTTX)?

BETTER THERAPEUTICS INC (BTTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.15).